In the News - View AAM CEO Dan Leonard's blog on the essential role generic drugs play during COVID-19
Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets
This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market. It is the first in a series of AAM papers that will highlight challenges to the overall sustainability of the generics and biosimilars industry.
AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines
Association for Accessible Medicines Unveils Policy Agenda for
Biden Administration and 117th Congress
Outlines Policy Solutions to Support Long-Term Sustainability of Generic and Biosimilar Medicines
New Campaign Highlights Lifesaving Role Generic Drugs Have Played in Treatment of COVID-19
Report Series Examines Threats to Patient Access and Affordability
Cancer Costs and Options for Care in the United States
In 2020, cancer claimed the lives of 600,000 Americans. According to the American Cancer Society (ACS CAN), there are approximately 1.7 million new cases of cancer in the United States each year, and more than 16.9 million Americans have a cancer history.
While We Await the Vaccine, We Can Trust in Generic Drugs
This article first appeared in Managed Healthcare Executive on February 1, 2021.
AAM’s Recommendations to #SecureOurMeds
Generic and biosimilar medicines are a proven solution to lowering drug costs, and the use of these medicines saved more than $313 billion in 2019 alone. At a time of high economic insecurity, access to more-affordable generic and biosimilars means patients are more likely to fill and use a generic drug prescription.
2021 Generics and Biosimilars Outlook
This article first appeared in Chain Drug Review on January 5, 2021 as Pharmacy Outlook: Dan Leonard.
Helen Knows She Can Rely on Biosimilars
Top 10 Ways to Commemorate 10 Years of Biosimilars in the U.S.
U.S. biosimilar medicines are 10 years old this year. It’s been an amazing journey so far, and we see great promise and opportunity ahead, with greater access and lower prices for patients with cancer, Crohn’s disease, rheumatoid arthritis and other conditions. Here are 10 ways to mark this auspicious anniversary:
10. Learn more about the 10th anniversary of the Biologics Price Competition and Innovation Act (BPCIA) at www.b10similars.org.
Jeni Got Her Life Back, Thanks to a Biosimilar
In 2019, Jeni Doerr finally received a diagnosis for her recent illnesses – pancolitis. Doerr, 35, from Newhall, CA, is featured in AAM’s recently released 2020 Generic Drug & Biosimilars Access & Savings in the U.S. report.